Skip to main content

Table 2 Average duration of untreated attacks

From: Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study

  Underweight BMI Normal BMI Overweight BMI Obese BMI
Baseline
Average duration of attack (h)
 n 12 150 106 41
 Mean ± SDa 50.7 ± 22.9 40.5 ± 32.4 45.9 ± 31.5 44.4 ± 35.5
 Median (range) 48.0 (6–92) 41.0 (0–140) 48.0 (0–156) 48.0 (0–120)
Follow-up
Average duration of attack (h)
 n 11 76 70 25
 Mean ± SDa 34.6 ± 21.6 39.7 ± 31.1 37.6 ± 30.6 44.2 ± 29.9
 Median (range) 36 (0–72) 37.5 (0–144) 28.7 (0–120) 48.0 (0.3–120)
  1. Average duration of untreated attacks corresponds to mean of average durations of untreated attacks at the skin, abdomen, larynx, and other sites
  2. BMI body mass index; SD standard deviation; n = the number of patients
  3. aP values comparing average duration of attack at baseline between patients with normal/overweight/obese BMI: P = 0.408 at baseline; P = 0.530 at follow-up. Results excluding data from the two reinjection outliers are presented in Additional file 1: Table S2